Abstract
Concussion, also known as mild traumatic brain injury (mTBI), commonly causes transient neurocognitive symptoms, but in some cases, it causes cognitive impairment, including working memory (WM) deficit, which can be long-lasting and impede a patient’s return to work. The predictors of long-term cognitive outcomes following mTBI remain unclear, because abnormality is often absent in structural imaging findings. Previous studies have demonstrated that WM functional activity estimated from functional magnetic resonance imaging (fMRI) has a high sensitivity to postconcussion WM deficits and may be used to not only evaluate but guide treatment strategies, especially targeting brain areas involved in postconcussion cognitive decline. The purpose of the study was to determine whether machine learning-based models using fMRI biomarkers and demographic or neuropsychological measures at the baseline could effectively predict the 1-year cognitive outcomes of concussion. We conducted a prospective, observational study of patients with mTBI who were compared with demographically matched healthy controls enrolled between September 2015 and August 2020. Baseline assessments were collected within the first week of injury, and follow-ups were conducted at 6 weeks, 3 months, 6 months, and 1 year. Potential demographic, neuropsychological, and fMRI features were selected according to their significance of correlation with the estimated changes in WM ability. The support vector machine classifier was trained using these potential features and estimated changes in WM between the predefined time periods. Patients demonstrated significant cognitive recovery at the third month, followed by worsened performance after 6 months, which persisted until 1 year after a concussion. Approximately half of the patients experienced prolonged cognitive impairment at the 1-year follow up. Satisfactory predictions were achieved for patients whose WM function did not recover at 3 months (accuracy = 87.5%), 6 months (accuracy = 83.3%), and 1 year (accuracy = 83.3%) and performed worse at the 1-year follow-up compared to the baseline assessment (accuracy = 83.3%). This study demonstrated the feasibility of personalized prediction for long-term postconcussive WM outcomes based on baseline fMRI and demographic features, opening a new avenue for early rehabilitation intervention in selected individuals with possible poor long-term cognitive outcomes.
Highlights
Mild traumatic brain injury, commonly referred to as concussion, typically does not present with visual findings on structural magnetic resonance imaging (MRI)examinations, and providing neuroimaging evidence to support a diagnosis or therapeutic evaluation is difficult
24 completed the baseline, and all four follow-up sessions were selected for investigations regarding dynamic changes in cognitive functions after a concussion
No significant within-group differences were observed in the demographics between patients who completed the 1-year follow-up and those who completed only the baseline assessment following concussion
Summary
Mild traumatic brain injury (mTBI), commonly referred to as concussion, typically does not present with visual findings on structural magnetic resonance imaging (MRI)examinations, and providing neuroimaging evidence to support a diagnosis or therapeutic evaluation is difficult. MTBI can cause an array of postconcussive symptoms (PCS), most notably headaches, sleep deficit, fatigue, dizziness, depression, anxiety, and cognitive impairment [1]. The average time required for symptom relief in most individuals is approximately 3 months [2]; some individuals with subjective PCS continue to experience symptoms even 1 year after a concussion [3,4]. Postconcussive neuropsychological deficits have been suggested to be secondary to cognitive deficits [5,6,7]. Studies have suggested that only 15% of first-time concussed individuals continue to experience persistent neuropsychological symptoms [8,9]; approximately half of them experience long-term cognitive impairment that persists for years and can severely affect their overall quality of life [10,11]. The options for the early treatment of mTBI remain rather limited due to a general lack of validated biomarkers with a high degree of sensitivity and specificity for the development of symptom-specific therapies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
